Combining targeted therapies to treat difficult lung cancer cases
Official title: Synergistic combination of Proteolysis Targeting Chimera with a translational formulation for the treatment of intractable lung carcinoma
Funded at St. John's University · NIH-10580447 · Data updated 2026-11-12
This study is testing a new way to treat advanced non-small cell lung cancer by using a special self-injectable medicine that targets specific proteins causing the cancer, with the hope of making treatments work better for patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. John's University NIH-funded |
| Lab location | 1 site (Queens, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $492,000 |
| NIH project number | 1R15CA271133-01A1 |
| Project ID | NIH-10580447 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have developed resistance to existing therapies.
✕Less likely to help
Patients with early-stage lung cancer or those without EGFR mutations may not benefit from this research.
What this research studies
This research investigates a new treatment approach for non-small cell lung cancer (NSCLC) by combining a novel drug delivery system with targeted therapies that degrade specific cancer-causing proteins. The study aims to develop a self-injectable, extended-release formulation that can effectively deliver these therapies to patients, potentially overcoming resistance to current treatments. By focusing on key oncogenic drivers like EGFR, KRAS, and MYC, the research seeks to improve treatment outcomes for patients with advanced lung cancer. Patients may be involved in trials to evaluate the safety and effectiveness of this new treatment method.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with resistant forms of lung cancer.
How similar studies have gone: While targeting multiple oncogenic drivers is a novel approach, similar strategies have shown promise in other cancer types, indicating potential for success in this area.
Where this research is happening
-
St. John's University
Queens, United States Active
Researchers
- Principal investigator: Patel, Ketankumar D. — St. John's University
- Study coordinator: Patel, Ketankumar D.
Related research
Other NIH-funded projects on the same topics.
-
Targeting immune vulnerabilities in small cell lung cancer
A physician-scientist is undergoing a five-year training program to understand how immune cells interact with small cell lung cancer and to build skills for a future independent lab career.
-
Investigating immune weaknesses in small cell lung cancer
This study is looking at how the immune system works with small cell lung cancer to find new ways to help it fight the disease, and it's designed for patients who want to learn more about potential treatments.
-
How small cell lung cancer cells switch between different states
This research looks at how cells inside small cell lung cancer change into different types and how those changes affect treatment for people with SCLC.
-
Understanding how small cell lung cancer adapts and resists treatment
This study is looking at small cell lung cancer to understand why it grows so quickly and resists treatment, using special models from patients to find new ways to improve care for people facing this tough disease.
-
A new treatment for squamous cell lung cancer using targeted therapy
This study is testing a new treatment for squamous cell lung cancer that uses a special drug designed to deliver chemotherapy directly to cancer cells, which could help patients feel better and live longer while protecting healthy tissues.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.